Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17539082 | 0.90 | GPR119 (0.41) | GPR119MCHR1GLSMAOAMAOB | |
| SCHEMBL27090581 | 0.81 | KCNJ1 (0.45) | MAOAMAOB | |
| SCHEMBL12152325 | 0.79 | TSHR (0.54) | GLSMAOAHTR2CSLC6A4HSD17B10 | |
| SCHEMBL17509606 | 0.79 | HTR2C (0.37) | MCHR1GLSHTR2CSLC6A4HSD17B10 | |
| SCHEMBL20951182 | 0.76 | GPR119 (0.42) | GPR119MAOAMAOBHSD17B1CASP1 | |
| SCHEMBL4813891 | 0.76 | CASP1 (0.49) | MAOAMAOBHSD17B1ACACBCASP1 | |
| SCHEMBL17539087 | 0.75 | KDM4E (0.56) | GLSHTR2CSLC6A4HSD17B10 | |
| SCHEMBL19236010 | 0.75 | MCHR1 (0.39) | MCHR1GLSHTR2CSLC6A4 | |
| SCHEMBL17509613 | 0.74 | HTR2C (0.37) | MCHR1GLSHTR2CSLC6A4HSD17B10 | |
| SCHEMBL23448763 | 0.73 | HRH3 (0.44) | GPR119GLSHTR2CSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9975848-B2 | Inhibitors of HIV-1 entry and methods of use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975848-B2 | Inhibitors of HIV-1 entry and methods of use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-05-22 | — | — | US | disclosed |
| US-9975848-B2 | Inhibitors of HIV-1 entry and methods of use thereof | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170233335-A1 | INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | BRYN MAWR COLLEGE | 2017-08-17 | — | — | US | disclosed |
| US-20170233335-A1 | INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | BRYN MAWR COLLEGE | 2017-08-17 | — | — | US | disclosed |
| US-20170233335-A1 | INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | BRYN MAWR COLLEGE | 2017-08-17 | — | — | US | disclosed |
| WO-2016025681-A1 | INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-02-18 | — | — | WO | disclosed |
| WO-2016025681-A1 | INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233335-A1 | INHIBITORS OF HIV-1 ENTRY AND METHODS OF USE THEREOF | CD4, CD81, ICAM1 | GPR119 3438/4885MCHR1 3750/4885GLS 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.